Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0XMUFR
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
B7H3-ADC-15 (DAR8)
|
|||||
| Synonyms |
B7H3 ADC 15 (DAR8)
Click to Show/Hide
|
|||||
| Organization |
Suzhou Medilink Therapeutics Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 4 Indication(s)
Astrocytoma [ICD11:2F36]
Investigative
Kidney cancer [ICD11:2C90-2C91]
Investigative
Melanoma [ICD11:2C30]
Investigative
Non-small cell lung cancer [ICD11:2C25]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
7.8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-B7H3 mAb 2E3-02
|
Antibody Info | ||||
| Antigen Name |
CD276 antigen (CD276)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
B7H3-ADC-15(DAR8) linker
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 1.02 ug/mL | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
|
||||
| In Vitro Model | Minimally invasive lung adenocarcinoma | NCI-H358 cells | CVCL_1559 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 1.18 ug/mL | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
|
||||
| In Vitro Model | Colon cancer | HT29 cells | CVCL_A8EZ | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.